Sucampo Pharmaceuticals, Inc. (SCMP)

[biotech_researcher]

Q313 US net sales of constipation drug Amitiza (by US partner Takeda) reached $72.5m (+1.4%) and we estimate FY13 sales at $280m. Amitiza is the only oral drug available for opioid-induced constipation, a significant opportunity. Amitiza holds further potential from its commercial roll-out in Japan (marketed by Abbott Japan) and in Europe (directly in the UK and Switzerland; with further partnerships possible). Sucampo is planning a Phase III programme for Amitiza in paediatric patients and has started a pivotal study with a liquid formulation. Rescula (unoprostone) is available for glaucoma in the US (since Feb 2013), and is being studied in Japan in a Phase III trial for retinitis pigmentosa, a significant unmet need.